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Abstract
Background: Currently molecular diagnostic laboratories focus only on the identification of large
deletion and duplication mutations (spanning one exon or more) for Duchenne Muscular
Dystrophy (DMD) yielding 65% of causative mutations. These mutations are detected by an existing
set of multiplexed polymerase chain reaction (PCR) primer pairs. Due to the large size of the
dystrophin gene (79 exons), finding point mutations (substitutions, deletions or insertions of one
or several nucleotides) has been prohibitively expensive and laborious. The aim of this project was
to develop an effective and convenient method of finding all, or most, mutations in the dystrophin
gene with only a moderate increase in cost.
Results: Using denaturing high performance liquid chromatography (DHPLC) screening and direct
sequencing, 86 PCR amplicons of genomic DNA from the dystrophin gene were screened for
mutations in eight patients diagnosed with DMD who had tested negative for large DNA
rearragements. Mutations likely to be disease-causative were found in six of the eight patients. All
86 amplicons from the two patients in whom no likely disease-causative mutations were found
were completely sequenced and only polymorphisms were found.
Conclusions: We have shown that it is now feasible for clinical laboratories to begin testing for
both point mutations and large deletions/duplications in the dystrophin gene. The detection rate
will rise from 65% to greater than 92% with only a moderate increase in cost.
Background
Dystrophinopathies are X-linked recessive diseases
caused by primary dystrophin deficiency, and include:
Duchenne Muscular Dystrophy (DMD), Becker Muscu-
lar Dystrophy (BMD), manifesting DMD/BMD carrier
females, X-linked dilated cardiomyopathy, isolated
quadriceps myopathy, muscle cramps with myoglobinu-
ria and asymptomatic elevation of muscle enzymes [1].
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The DMD gene spans 2.4 million base pairs of genomic
DNA on the X chromosome and its 14 kb transcript en-
codes a full-length protein (dystrophin) of 427 kiloDal-
tons. Dystrophin is a sarcolemmal protein that through
its interaction with many other proteins participates in
the linkage of the extracellular matrix to the cytoplasmic
cytoskeleton [2–4]. Mutations in this gene result in
DMD, BMD or other dystrophinopathy. A major conse-
quence of the dystrophin gene's large genomic size is a
high rate of mutation; close to 30% of cases prove to be
spontaneous mutations[5]. Approximately 60% of muta-
tions causing DMD are deletions of large segments of the
gene usually including one or more exons [6–8]. Approx-
imately 5% of mutations are duplications of large seg-
ments of the gene[8]. Large deletions and duplications
are detected using multiplexed PCR primers to amplify a
subset of (approximately 20 of the 79) exons that are em-
pirically estimated to constitute 98% of large deletions
and duplications. Thus, most but not all large deletions
and duplications are detected by this test[9,10]. The oth-
er 35% of mutations are presumed to be point mutations
such as, substitutions, deletions or insertions of one or
several nucleotides leading to premature termination co-
dons (nonsense or frame-shift mutations), amino acid
substitutions (missense and neutral mutations) and al-
terations in splice sites. These mutations have remained
undetected in most patients, both male and female, be-
cause available techniques are relatively expensive and
laborious given the size of the dystrophin gene. Existing
procedures for detection of point mutations include
SSCP (single strand conformational polymorphism)
[11,12], a variation of SSCP called DOVAM (Detection of
Virtually All Mutations) [19], Enhanced SSCP [28], HA
(Heteroduplex Analysis) [13,14], PTT (Protein Trunca-
tion Test)[15], DGGE (Denaturing Gradient Gel Electro-
phoresis) [16–18], chemical cleavage of mismatch[20],
and RNase cleavage[21]. Each of these procedures has its
advantages and limitations but the size of the gene and
the cost of the procedures have not made them routine in
most laboratories.
The purpose of this project was to develop an effective
and convenient process to detect both large and small al-
terations in the DMD gene with only a moderate increase
in cost. In an effort to address these issues, we developed
a new primer set to be used in conjunction with denatur-
ing high-performance liquid chromatography (DHPLC)
and dye-terminator sequencing. DHPLC has been devel-
oped to screen for DNA variations by separating heter-
oduplex and homoduplex DNA fragments by ion-pair
reverse-phase liquid chromatography [22]. We used this
technique to study eight male patients and one female
carrier relative of one of the eight males. Since this tech-
nique separates heteroduplexes and homoduplexes, it
can also be used to analyze manifesting and carrier fe-
males with point mutations.
Results
We started the project with the intention of designing
primers to amplify and sequence all of the exons of the
dystrophin gene as well as the 3'-UTR and 5'-UTR. In or-
der to ensure detection of splice site as well as exon se-
quence alterations, genomic sequence surrounding each
of the sequence-known fragments of dystrophin was
mined from the NIH GenBank database. Primers were
designed (see methods) that allowed for amplification of
a product with 30 – 100 bases on either side of each ex-
on. To look for point mutations, eight patients were cho-
sen as test cases based on the absence of dystrophin,
clinical symptoms consistent with DMD and no large de-
letion or duplication detected by the multiplexed PCR
test. In addition, one sister thought to be a carrier female
was also tested as described in the methods and summa-
rized in Table 1.
Initially the primers were used to prepare amplicons of
dystrophin exons for direct sequencing. Likely disease-
causative mutations were found in four of the patients
and confirmed in the female relative of patient 01 by di-
rect sequencing of exons 2 through 55, and the three 5'-
Table 1: Patient Medical Records Information
Patient Pathology Dystrophin CPK At
Number Analysis1 (IU/L)2 Age
(years)
01 Consistent with Absent 12,500 6.5
DMD
02 Consistent with Absent 15,000 6.5
DMD
03 Consistent with Absent 15,820 4.0
DMD
04 Consistent with Absent 23,000 5.5
DMD
053 Consistent with Absent with 
rare
21,000 2.5
DMD positive fib-
ers
06 Consistent with Absent 14,000 7.5
DMD
07 Consistent with Absent 11,906 3.7
DMD
08 Consistent with Absent 14,000 4.0
DMD
1Dystrophin analysis by either western blot or immunohistochemistry 
or both. 2Normal range of CPK level is 0–250 IU/L. 3Patient 05 was 
also tested for the sarcoglycans and all were found presentBMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
UTR fragments, the last of which includes the dp427m
promoter and exon 1. These were sequenced prior to our
obtaining the DHPLC system for screening. When a like-
ly disease-causative mutation was found in each of these
patients, no further fragments were sequenced for that
patient. Patient 01 and his carrier sister were shown to
have a C->T substitution in exon 39 bp5762, predicting a
nonsense mutation Gln->Stop, leading to a likely dis-
ease-causative truncation of the protein (Table 2 and
Figure 1).
Patient 02 has an 11 bp deletion in exon 41 and patient 03
is missing exon 21 which was not recognized until the
end of the project and had not been detected by the mul-
tiplexed PCR test because exon 21 is not one of the in-
cluded exons in that test. These two mutations both
create out of frame transcripts leading to eventual stop
codons and premature truncation of the protein. Patient
07 has a C->T substitution in exon 23 at bp 3359 predict-
ing a nonsense mutation Arg->Stop, leading to a likely
disease-causative truncation of the protein. Patient 04
has a G->T substitution at base 738+1 of the intron 6
splice site. This donor splice site is normally a G but in
1805 sites examined in the human genome, only 8 times
is it a T[23]. The predicted aberrant splicing of exon 7
makes this a likely causative mutation in this patient.
The DHPLC system was obtained halfway into the study
and four patients' exons 56 through 78 and the 3'-UTR
including exon 79 were analyzed on the DHPLC system
prior to sequence analysis. In the DHPLC system, frag-
ments are screened for variation in retention time or
chromatogram shape from that of an unaffected control
amplicon. Fragments exhibiting variation are then se-
quenced for confirmation and analysis. Two variations
were detected by DHPLC, both in exon 59, for patients
05 and 06 (Figure 2a) (only patient 06 shown). These
two fragments were sequenced and a non-disease-causa-
tive Gln->Arg missense mutation at bp 9018 was found
in both patients. As we found no likely disease-causative
mutations in our first pass DHPLC conditions, we se-
quenced all four patients exons 56–78 and the 7 frag-
ments of the 3'-UTR (the first of which contains exon 79).
Only two of the 116 fragments (4 patients x 29 fragments
each) sequenced showed alterations which were not de-
tected by the first pass temperatures chosen for DHPLC
analysis. The first is a polymorphism, 9857+15 C->T in
intron 66, in patient 06. The second is a probable novel
disease-causative mutation, 10015+5 G->A in intron 67,
within the splice site consensus sequence in patient 08.
Based on 1788 donor sites from the human genome, 128
(7.16%) were adenosine while 1468 (82.1%) were guano-
sine at this position in the splice sequence making it like-
ly that exon 68 will be aberrantly spliced[23]. When
these two fragments were run on the DHPLC system at
the lower second pass temperatures indicated in
1Additional file A: Primer sequences and DHPLC tem-
peratures Excel spreadsheet, the alterations were detect-
ed (Figure 2c and 2b). In addition, the four previously
Figure 1
Electropherograms of dystrophin exon 39 sequence from
Patients 01 and 01S UM-39F: Unaffected Male-Exon39 For-
ward UM-39R: Unaffected Male-Exon39 Reverse 01: Patient
01 01S: sister of patient 01
UM-39F
UM-39R
01S-39F
01S-39R
01-39F
01-39RBMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
Table 2: Alterations found.
Alteration Nature of alteration Status of alteration
 
Location of alteration residue Patient number
 
C->T; Gln-Stp Causative Known 5762 1852 01 & 01S
exon 39
Del 11 bases Causative Unknown 6056–6066 1950–1953 02
exon 41
Del exon 21 Causative N/A 03
G->T; Splice Causative Unknown 738+1 04
destroyed ex6
C->T; Arg- Causative Unknown 3359 1051 07
>Stp exon 23
G->A Splice Causative Unknown 10015+5 08
destroyed 67
C->T;Arg- Neutral Known 6671 2155 03
>Trp ex45
G->A;Arg- Neutral Known 5442 1745 05,06,08
>His ex37
A->G;Gln- Neutral Known 9018 2937 05,06
>Arg ex59
C->T;Arg- Neutral Known 6779 2191 06
>Trp ex45
G->A;Gly- Neutral Known 2853 882 08
>Asp21 ex21
A->G;Arg- Silent2 Unknown 1843 545 05,08
>Arg ex14
G->A;Ser- Silent Known 3229 1007 08
>Ser ex23
CC->GA Intronic Unknown 1040–18 04
before ex09
G->T before Intronic Unknown 1691–123 04,05
ex13
T->C before Intronic Unknown 1913–57 05,08
ex15
T->C before Intronic Unknown 6326–150 05
ex 43
G->T after Intronic Unknown 6822+25 06,08
ex45
T->C after Intronic Unknown 2376+17 06
ex17
10A's->8A's Intronic Unknown 6130+69 06,08
after ex41
T->C before Intronic Unknown 2377–96 08
ex18
C->T after Polymorphic Known 8235+11 03
ex54
G->A before Polymorphic Known 1691–110 04,05
ex13
C->G after Polymorphic Known 7408+53 04
ex49
T->C before Polymorphic Known 1691–72 05
ex13
A->T before Polymorphic Known 6326–63 05
ex43
C->T after Polymorphic Known 9857+15 06
ex66
1Alterations were compared to Leiden Muscular Dystrophy pages  [http://www.dmd.nl/]  to determine if know or previously unknown. 2Potential 
splice site created.BMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
Figure 2
DHPLC chromatograms of unaffected male vs. patient a: patient 06 exon 59 A->G bp 9018 b: patient 08 exon 67 G->A bp
10015+5 c: patient 06 exon 66 C->T bp 9857+15
 
(a) (b)
(c)BMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
Figure 3
DHPLC chromatograms of unaffected male vs. patient a: patients 01 and 01s exon 39 C-> T bp 5762 b: patient 02 exon 41 del
6056–6066 c: patient 04 exon 06 G->T bp 738+1 d: patient 07 exon 23 C->T bp 3359
 
 
(a) (b)
(c) (d)BMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
identified mutations were confirmed on the DHPLC sys-
tem, as was the carrier status of patient 01S (Figure 3).
In total, likely disease-causative mutations were found in
six of the eight male patients and confirmed in the carrier
sister (patient 01s) of one of the six patients (patient 01).
In addition, one silent and five neutral polymorphisms,
and six intronic alterations that have previously been
shown to be present in unaffected individuals were
found. One silent polymorphism and eight previously
unreported intronic alterations were also found. In two
patients, 05 and 06, we did not find likely disease-causa-
tive mutations despite sequencing all 86 fragments.
Discussion
We used a combination of direct sequencing and DHPLC
to search for mutations in 8 patients with DMD and a
carrier sister. Likely causative mutations were found in 6
of 8 males and confirmed in the carrier sister of one. In
our study, one likely causative mutation (patient 03 del
exn21) was found just by PCR analysis and 5 likely caus-
ative mutations were first detected by direct sequencing
but each was subsequently detected by DHPLC. Our ex-
perience indicates that the multiple different conditions
of DHPLC would have detected all of these likely causa-
tive mutations and all polymorphisms. Direct sequenc-
ing of all the fragments is still more costly than DHPLC
and our results indicate that initial analysis using the far
cheaper DHPLC should precede sequencing thus reduc-
ing cost of the analysis. Causative mutations were not
found in two of the eight patients. Due to the enormous
size of the dystrophin gene (2.4 million base pairs), find-
ing 100% of mutations is improbable using these frag-
ments because we cannot examine all the sequences and
situations that might affect expression. It is possible, but
unlikely, that one of the currently unknown alterations
that we found in patients 05 and 06 will eventually be
proven a causative mutation rather than a polymor-
phism.
Two of the patients in which we found disease-causative
mutations have affected brothers, three in addition to
patient 01, have potential carrier sisters, and all six have
mothers who could also be carriers. We have shown that,
1) using the DHPLC system, it is now not only feasible
but actually a simple process to determine if any of these
relatives have the same point mutation as their brother/
son and, 2) that carrier testing and pre-natal diagnostic
testing is now available to any of these patients who wish
to use it.
As larger cohorts of patients are tested, a more accurate
estimate of the percentage of undetectable causative mu-
tations will emerge and present a clear new challenge.
We estimate based on our small sample, and other un-
published data, that such cases will comprise a small per-
centage (less than 8 percent) of total DMD cases.
Possible explanations for such cases include duplications
which we may have missed, mutations in unknown en-
hancers or translation modifiers hidden in exons or in-
trons, mutations that create novel splice sites and
changes in the coding region which might be pathogenic
but which, due to our lack of knowledge, are thought to
be polymorphic. For example, changes to an amino acid
that is essential for some protein/protein interaction
(potentially transportation), or is modified/processed on
the protein level but which we currently assume is just a
polymorphic change. Other possible mechanisms in-
clude mosaicism, in which DNA extracted from blood
lymphocytes has different sequence than DNA extracted
from muscle cells, and cryptic chromosomal rearrange-
ments. These will require dedicated efforts to resolve ei-
ther individually case by case or to develop new, more
comprehensive, routine tests, including RNA and pro-
tein analysis. Fortunately, there are other methods for
detection of point mutations that can be compared to, or
used in addition to, the method presented here, includ-
ing PTT[15], DGGE[18], and DOVAM-S[19]. More infor-
mation on DGGE analysis of the DMD can be found in
the Leiden Muscular Dystrophy web site  [http://
www.dmd.nl/] .
Clinical laboratories planning to begin testing for point
as well as large mutations must clearly evaluate possible
technologies in at least three areas: effectiveness, con-
venience and cost.
DHPLC followed by sequencing improves the effective-
ness of mutation detection from 65%, using the existing
multiplexed PCR technology that detects large mutations
only, to approximately 92% by including detection of ap-
proximately 75% of point mutations as well. Clinical lab-
oratories that are planning to screen cohorts of patients
using the technique presented here will produce three
important outcomes. The first will be a more accurate
measure of the effectiveness of DHPLC screening for se-
quence variation followed by direct sequencing. The sec-
ond will be improvements in the conditions for mutation
detection using DHPLC. As new mutations are discov-
ered, they could be entered into the database along with
any suggested improvements to the DHPLC conditions
for a given fragment/alteration. The third will be a col-
lection of DNA, RNA and tissue from patients for whom
all 86 fragments were sequenced with no likely disease
causing mutations detected. This will prove extremely
useful for further investigations into the more subtle
causes of dystrophin-deficient muscular dystrophy. Ulti-
mately, this will provide procedures for the detection of
mutations in dystrophin-absent patients that will be
more comprehensive.BMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
The convenience of DHPLC followed by sequencing is
readily apparent. It requires neither radioisotopes nor
ethidium bromide gels when combined with a core se-
quencing facility or capillary sequencer (See 2Additional
file B for details).
We found that the cost of reagents for DHPLC screening
followed by direct sequencing was only moderately high-
er than the cost for the existing multiplexed PCR test.
The reagent cost of the existing multiplexed PCR diag-
nostic is estimated at $25.00 per patient. Increasing the
percentage of mutations detected in patients from the
current 65% to approximately 92% by including point
mutations would come at the moderate increase in rea-
gent costs of approximately $57.75 per patient plus a
moderate increase in other costs such as consumables
and technician time. Although the initial investment in a
DHPLC system is not minimal at approximately
$80,000, the cost can be amortized over many patients
and the DHPLC system can be used in the molecular di-
agnosis of many other diseases in addition to DMD. The
same, of course, is true for the purchase of an automated
sequencer. Details of the reagent costs per patient calcu-
lations are attached as 1Additional file A. Briefly, we as-
sumed that likely disease-causative mutations would be
found, on average, within approximately 43 fragments.
We calculated the cost of reagents per 50µl PCR and the
cost of reagents to run a sample on the DHPLC system
and multiplied by the number of samples required to
screen a patient. We estimated that there will be four
fragments per patient that require sequencing. We calcu-
lated the reagent costs to amplify, purify and sequence
these four strands per patient in both directions. We then
combined the cost of the existing multiplex test for 100%
of patients with the cost of DHPLC screening followed by
direct sequencing for 35% of patients to arrive at an av-
erage cost per patient and the increase over the average
cost per patient for the existing multiplexed PCR test
alone.
Conclusion
Point mutations can be found in both DMD/BMD male
patients and asymptomatic or manifesting DMD/BMD
carrier females via an effective and convenient process
using automated DHPLC screening for variation and di-
rect sequencing for confirmation and analysis at a mod-
erate increase in cost per patient. We have shown that it
is now feasible for clinical laboratories to begin testing
for both point mutations and large mutations in the dys-
trophin gene using this or one of the other available
methods for mutation detection. The detection rate for
all mutations in the DMD gene can be increased from the
present 65% to above 92%.
Materials and Methods
Patient materials
After reviewing medical records, we studied eight male
patients who had been diagnosed as having DMD based
on pathology lab report, disease progression and abnor-
malities in the level of dystrophin expression either by
immunofluorescence or western blot analysis. In each
patient, no large deletion or duplication was detected us-
ing the currently used primers. This current set consists
of primers to amplify the dp427m promoter including
exon 1 and exons 3, 4, 6, 8, 12, 13, 17, 19, 43, 44, 45, 47,
48, 49, 50, 51, 52, 60. Although none of the patients had
a family history of DMD, all were determined to be highly
likely to have dystrophin gene mutations, as opposed to
other genetic causes of muscular dystrophy (see Table 1).
Genomic DNA was prepared from whole blood using the
Puregene kit (Gentra Systems, Minneapolis, Mn.). DNA
concentration was determined by spectrophotometry.
This study was approved by the Children's Hospital insti-
tutional review board, and informed consent was ob-
tained from all adult participating subjects and from
parents or legal guardians of participating minors.
Primer/fragment design
Exonic and intronic sequence for dp427m was obtained
from NCBI/Genbank using an iterative electronic data
mining approach via the National Center for Biotechnol-
ogy Information web site pages for Blast searches and
Entrez queries  [www.ncbi.nlm.nih.gov/blast/Blast.cgi]
and  [http://www.ncbi.nlm.nih.gov/entrez/query.fc-
gi?db=Nucleotide] . Starting with known mRNA se-
quence (accession # Ml 8533), the accession numbers
referenced (Table 3) contain most of the sequence ob-
tained. Many compromises are involved in selection of
primer sequences. The primers listed in 1Additional file
A: Primer sequences and DHPLC temperatures Excel
spreadsheet were designed using the Primer3 (Whitehe-
ad Institute, Cambridge, Ma.) and OLIGO 6.0 (Molecu-
lar Biology Insights, Inc., Cascade, Co.) software
packages with four goals in mind. These were:
a) to include 30–100 bases of intronic sequence adjacent
to each exon at both the 5' and 3' ends of the exon
b) to create a single, visible, specific band of reasonable
intensity when analyzed on agarose gel
c) to create fragments that have melting characteristics
appropriate for cost-effective DNA variation screening
by DHPLC analysis. Appropriate melting characteristics
are such that variations from unaffected sequence in any
portion of the fragment will be detected using ideally
only one running temperature but no more than threeBMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
(see Additional file A: Primer sequences and DHPLC
temperatures Excel spreadsheet)
d) to provide clean sequence in both directions without
resorting to additional primers designed simply for se-
quencing the amplicon.
All these goals were met by the primer set presented
here. The primer set and the sequence of the fragments
as well as additional intron sequence are available on the
Leiden Muscular Dystrophy pages  [http://
www.dmd.nl/DMD_DHPLC.html] . Obviously, many of
these primers could be grouped into sets for multiplex
PCR in order to initially screen for large mutations using
the same primers presented here. Multiplexed PCR
could be run on the DHPLC system in a size detection
mode for detection of large deletion/duplication altera-
tions in males. A page or process could be provided with-
in the Leiden Muscular Dystrophy pages for posting of
suggested improvements to DHPLC conditions for de-
tection of specific alterations and for suggested primer
design improvements. Quantitative PCR, FISH (Fluores-
cent In-Situ Hybridization) or MAPH (see  [http://
www.dmd.nl/DMD_MAPH.html] ) analysis is still re-
quired for detection of female carriers of large deletion/
duplication alterations. Quantitative PCR can be per-
formed on the DHPLC system, the ABI 7700 Sequence
Detector, the Bio-Rad iCycler or by standard densitomet-
ric procedures.
Amplification of genomic DNA
DNA was amplified in a final reaction volume of 50 µl by
using 100 ng genomic DNA, 10x buffer (ABgene Thermo
Start AB-0908/b, ABgene, Epson, Surrey, KT19 9AP,
U.K.), 1.5 mM MgCl2, 200 µM each dNTPs, 0.27 µM(100
ng) primers and 1.25 units Thermo Start polymerase
(Abgene).
PCR cycling conditions consisted of an initial denatura-
tion step at 95°C for 15 min. followed by 35 cycles of 94°C
for 5 s, the specified annealing temperature (indicated in
1Additional file A: Primer sequences and DHPLC tem-
peratures Excel spreadsheet) for 15 s, 72°C for 30 s and
ending with a final elongation step at 72°C for 3 min.
WAVE® system DHPLC analysis
The DHPLC instrument we used is the WAVE® system
(Transgenomic Inc., Omaha, Ne.). Unpurified PCR am-
plicons from patients were mixed in a 1:1 ratio with an al-
iquot of unpurified PCR amplicon from an unaffected
male. The unaffected male amplicon and the mix were
heated to 95°C for 5 min. and cooled slowly over 45 min.
to 25°C in a thermocycler. The unaffected and mixed re-
actions were then run at pre-determined temperatures
(see 1Additional file A: Primer sequences and DHPLC
temperatures Excel spreadsheet) on the WAVE® system
and the resultant chromatograms compared for varia-
tion in shape or retention time. Figure 4a depicts typical
chromatograms for samples in which no variation from
unaffected control is detectable. Figure 4b and 4c show
the mutation and size standards. We recommend that
the first five injections of each run should be a blank (0
volume), the size standard, a blank, the mutation stand-
ard and a blank. The retention time and peak/trough
height of the standards should be compared to those ob-
tained the very first time the standards were run (at in-
stallation of the system) to ascertain the separation
performance of the column. If they vary by more than
10%, the run should be aborted and the column cleaned
or other preventative/curative steps taken to return the
system to operation within the specifications for the
standards as stated in the systems manual.
Sequence analysis
PCR amplicons were purified using the QIAquick PCR
Purification Kit (Qiagen, Valencia, Ca.). DNA concentra-
tion was determined by spectrophotometry. Cycle se-
quencing extension products were created in a final
volume 20 µl reaction using 8 µl H2O, 4 ul forward or re-
verse primer at 20 ng/µl, 4 µl template DNA (amplicon)
at 4 ng/µl for fragments up to 200 bp, 5 ng/µl for frag-
ments between 200 and 400 bp and 6 ng/µl for frag-
ments greater than 400 bp, 2 µl Big Dye Terminator
Ready Reaction mix (PE-ABI, Foster City, Ca.) and 2 µl
HalfBD (Genepak, Inc. Stony Brook, N.Y.).
Table 3: Genomic sequence sources.
Approximate locus Accession Number
5'UTR, muscle promoter, and Exon 1 M32058
Exon 2 AL139401
Exon 6 AL121880
Exon 7 U60822
Exon 8 L08092
Exon 9 U06836
Exon 10 AC004468
Exon 17 AL031542
Exon 44 AC069170
Exon 47 AC021166
Exon 51 AC079864
Exon 52 AC025935
Exon 56 AC079175
Exon 57 AC079177
Exon 63 AC078958
Exon 72 AC079143
3'UTR and Exon 79 AC006061
Genomic sequence found in Genbank using the referenced accession 
number includes the referenced exon an often several other nearby 
exons and surrounding intron sequence.BMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
Figure 4
DHPLC chromatograms for variation negative condition and standards a: Typical chromatograms as seen when no variation
exists between unaffected control and patients b: Mutation standard c: Size standard
 
(a) (b)
(c)BMC Genetics 2001, 2:17 http://www.biomedcentral.com/1471-2156/2/17
Cycle sequencing conditions consisted of an initial dena-
turation step at 95°C for 4 min. followed by 25 cycles of
95°C for 12 s, 49°C for 6 s, and 60°C for 4 min. Unincor-
porated dye and other contaminants were removed with
SEQueaky Kleen 96 well kit (BIO-RAD Laboratories,
Hercules, Ca.) Both strands were sequenced on an ABI
373 automated sequencer. Data was analyzed with the
SequencherTM software (Genecodes Inc. Ann Arbor,
Michigan).
Abbreviations
DHPLC: Denaturing high performance liquid chroma-
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DMD: Duchenne Muscular Dystrophy
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